Abstract

The Dana-Farber Cancer Institute is an independent teaching affiliate of the Harvard Medical School and supports a federally-designated Comprehensive Cancer Center.
The aims of the Institute's Center can be summarized as follows: (a) to develop and maintain clinical and laboratory research programs of high quality related to the biology, cause and prevention, diagnosis and treatment of cancer. (b)to serve as the major cancer center in the Harvard-Longwood medical area and to play a leadership role for cancer research in New England providing expertise in cancer diagnosis, treatment and prevention. (c) to participate in the research training of medical students, house staff, fellows and graduate students and to provide post-doctoral research training. To maintain these activities, the present application requests renewal of the Institute's Cancer Core Support Grant. In addition, as a Comprehensive Cancer Center, the institute aims to translate its research findings to provide optimal care for cancer patients and to add to the total oncology resources of the local and regional medical communities in terms of staff, facilities and expertise.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006516-36S1
Application #
6167811
Study Section
Cancer Center Support Review Committee (CCS)
Program Officer
Ptak, Krzysztof
Project Start
1977-12-01
Project End
2000-06-30
Budget Start
1999-02-01
Budget End
2000-06-30
Support Year
36
Fiscal Year
2000
Total Cost
$1,558,610
Indirect Cost

  Institution

Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215

  Publications

Choudhury, Atish D; Gray, Kathryn P; Supko, Jeffrey G et al. (2018) A dose finding clinical trial of cabozantinib (XL184) administered in combination with abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate :
Watson, Noreen L; Mull, Kristin E; Heffner, Jaimee L et al. (2018) Participant Recruitment and Retention in Remote eHealth Intervention Trials: Methods and Lessons Learned From a Large Randomized Controlled Trial of Two Web-Based Smoking Interventions. J Med Internet Res 20:e10351
Pednekar, M S; Nagler, E M; Gupta, P C et al. (2018) Scaling up a tobacco control intervention in low resource settings: a case example for school teachers in India. Health Educ Res 33:218-231
Braun, Danielle; Yang, Jiabei; Griffin, Molly et al. (2018) A Clinical Decision Support Tool to Predict Cancer Risk for Commonly Tested Cancer-Related Germline Mutations. J Genet Couns 27:1187-1199
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917

Showing the most recent 10 out of 411 publications